

# Resource Summary Report

Generated by [dkNET](#) on Sep 2, 2026

## Recombinant Anti-IL-6 antibody [EPR23819-103]

RRID:AB\_3064891

Type: Antibody

---

### Proper Citation

Abcam Cat# ab290735, RRID:AB\_3064891

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_3064891](http://antibodyregistry.org/AB_3064891)

**Proper Citation:** Abcam Cat# ab290735, RRID:AB\_3064891

**Target Antigen:** IL-6

**Host Organism:** rabbit

**Clonality:** recombinant monoclonal

**Comments:** Applications: ICC/IF, IHC-P, WB, IHC-Fr

**Antibody Name:** Recombinant Anti-IL-6 antibody [EPR23819-103]

**Description:** This recombinant monoclonal targets IL-6

**Target Organism:** mouse

**Clone ID:** EPR23819-103

**Antibody ID:** AB\_3064891

**Vendor:** Abcam

**Catalog Number:** ab290735

**Record Creation Time:** 20250820T044314+0000

**Record Last Update:** 20250820T194503+0000

---

### Ratings and Alerts

No rating or validation information has been found for Recombinant Anti-IL-6 antibody [EPR23819-103].

No alerts have been found for Recombinant Anti-IL-6 antibody [EPR23819-103].

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 5 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [dkNET](#) .

Ding N, et al. (2026) Gut microbiota-derived isovaleric acid alleviates atrial fibrillation by suppressing GSDME-dependent pyroptosis. *Cell metabolism*, 38(2), 370.

Dong X, et al. (2026) Synthetic cleavage-resistant TREM2 boosts macrophage efferocytosis to treat inflammatory diseases. *Cell reports. Medicine*, 7(2), 102580.

Chen L, et al. (2026) Bilirubin mitigates ischemic white matter injury by targeting transferrin-receptor-mediated B cell immunometabolism. *Cell reports*, 45(6), 117398.

Yang Z, et al. (2025) Cross-species tropism of AAV.CPP.16 in the respiratory tract and its gene therapies against pulmonary fibrosis and viral infection. *Cell reports. Medicine*, 6(6), 102144.

Park SA, et al. (2025) IA-0130, a novel 3-(1,3-diarylallylidene)oxindole derivative, alleviates ovarian cancer via inhibiting IL-6/gp130/STAT3 signalling. *British journal of pharmacology*.